 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Sarcoma - General
|
|
Neoadjuvant Chemotherapy with Regional Hyperthermia Improves Outcomes for Soft Tissue Sarcoma (10/5/2009)
Researchers affiliated with EORTC-ESHO Intergroup Trial (NCI-00003052) have reported that neoadjuvant chemotherapy with regional hyperthermia (RHT) improves outcomes of patients with high-risk soft tissue sarcoma (STS) compared with standard neoadjuvant chemotherapy. The results of this randomized study were presented on September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.
Adjuvant Gleevec® Improves Recurrence-free Survival of Patients with Gastrointestinal Stromal Tumors (3/24/2009)
Researchers affiliated with the American College of Surgeons Oncology Group (ACOSOG) Intergroup GIST Study Team have reported that adjuvant Gleevec® (imatinib mesylate) improves recurrence-free survival of patients with gastrointestinal stromal tumors (GIST). The details of this study appeared in an early online publication in The Lancet on March 19, 2009.
Allogeneic Stem Cell Transplantation Effective for Myeloid Sarcoma (10/22/2008)
Researchers from France have reported that approximately one-third of all patients with myeloid sarcoma (granulocytic sarcoma, choloroma) become long-term disease-free survivors following allogeneic stem cell transplantation. The details of this study appeared in the October 20, 2008 issue of the Journal of Clinical Oncology.
Adjuvant Chemotherapy Confirmed Beneficial for Resectable Soft Tissue Sarcoma (7/24/2008)
Canadian researchers have reported that adjuvant chemotherapy improves outcomes of adult patients with localized soft tissue sarcoma (STS). The details of this study appeared in the August 1, 2008 issue of Cancer.
Dose-dense Chemotherapy Effective for Localized Ewing’s Sarcoma (6/11/2008)
Researchers affiliated with the Children’s Oncology Group (COG) have reported that chemotherapy given every two weeks is more effective than chemotherapy given every three weeks in patients with localized Ewing’s Sarcoma. The details of this study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2.
Outcomes of Older Patients with Localized Ewing’s Sarcoma Similar to Younger Patients (2/16/2007)
Researchers from Italy have reported that patients over the age of 40 with localized Ewing’s sarcoma have outcomes similar to that of younger patients and should be treated on the same protocols.
PET Useful for Initial Evaluation of Children with Rhabdomyosarcoma (2/14/2007)
Researchers from Memorial Sloan-Kettering Cancer Center have reported that PET is a useful test for the initial staging of children with rhabdomyosarcoma.
Camptosar® Confirmed Active in Recurrent or Refractory Rhabdomyosarcoma (2/13/2007)
Two clinical trials published in the January 2007 issue of the Journal of Clinical Oncology suggest that Camptosar (irinotecan) has significant activity and is well tolerated drug for the treatment of recurrent and refractory rhabdomyosarcoma.
Taxotere® plus Gemzar® is an Effective Regimen for Advanced Soft-Tissue Sarcomas (4/4/2006)
Researchers from France have reported that the combination of Taxotere® (docetaxel) and Gemzar (gemcitabine) may improve outcomes of patients with locally unresectable or metastatic soft-tissue sarcoma (STS).
ICE Plus CAV Intensification Promising for High Risk Ewing’s Sarcoma (3/31/2006)
Researchers from Italy have reported that an induction regimen of ifosfamide, carboplatin and etoposide (ICE) followed by intensification with cyclophosphamide, doxorubicin, and vincristine results in an estimated 67% 3 year survival in patients with Ewing’s sarcoma.
Surgical Resection of Recurrent Rhabdomyosarcoma Can Be Effective Therapy (3/31/2006)
Researchers from the Children’s Cancer Hospital of the University of Texas M.D. Anderson Cancer Center have reported that one third of children with recurrent rhabdomyosarcoma can be salvaged with aggressive surgery.
Molecular Markers Detect Minimal Disseminated Disease in Rhabdomyosarcoma (3/30/2006)
Researchers from Italy have reported that molecular markers are superior to morphologic assays for the detection of minimal disseminated disease in patients with rhabdomyosarcoma.
Isolated Limb Perfusion with Tumor Necrosis Factor and Alkeran® is Effective for Soft Tissue Sarcoma (3/21/2006)
Researchers from the Netherlands have reported that isolated limb perfusion with tumor necrosis factor-alfa (TNF-alfa) and Alkeran (melphalan) can provide limb salvage in a significant fraction or patients with locally advanced soft tissue sarcoma (STS).
Gleevec Has Activity for Treatment of Aggressive Fibromatosis (3/20/2006)
A multicenter trial has determined that Gleevec (imatinib) treatment of advanced aggressive fibromatosis (desmoid tumor) is associated with a 16% response rate and a disease stabilization rate of 68%.
Avastin® Adriamycin Combination for Soft Tissue Sarcoma (3/8/2006)
A multicenter trial has suggested that the addition of Avastin (bevacizumab) to Adriamycin (doxorubicin) improves outcomes of patients with metastatic soft tissue sarcoma (STS).
Cytogenetics Help Predict Outcomes of Soft Tissue Sarcomas (3/7/2006)
Researchers from Sweden have reported that cytogenetic examination of soft tissue sarcomas (STS) helps predict the development of metastatic disease in adult patents. This should assist in designing more aggressive therapy for high-risk patients.
Neoadjuvant Chemotherapy and Radiotherapy Promising for Large Soft Tissue Sarcomas (3/3/2006)
Researchers affiliated with the Radiation Therapy Oncology Group Trial 9514 have reported that combined modality treatment may improve disease-free survival and prevent amputations in patients with high-grade, high-risk soft tissue sarcoma (STS).
Autologous Stem Cell Transplants May Improve Outcomes of Relapsed Ewing’s Sarcoma (8/1/2005)
Researchers from the Fred Hutchinson Cancer Research Center (FHCRC) have reported that high-dose chemotherapy and autologous stem cell transplantation may improve survival in patients with chemotherapy response relapse of Ewing’s sarcoma.
Onyvax-105 Shows Promising Results in Osteosarcoma (5/3/2005)
Researchers affiliated with the UK Children’s Cancer Study Group have reported that a vaccine known as Onyvax-105 (105AD7 ) elicits an immune response in patients with osteosarcoma.
Localized Pelvic Ewing Sarcoma has a Worse Prognosis Than Localized Involvement of Other Bones (2/20/2003)
The Ewing sarcoma group of tumors occurs in late childhood and early adulthood and involves the bone. Approximately 25% occur in the pelvis and approximately 40% occur in one of the three leg bones. However, it is generally considered that Ewing sarcoma involving the pelvis has a worse prognosis than other sites. This may be due to delay in diagnosis which results in a larger tumor size at presentation. In the February 2003 issue of the
Journal of Pediatric Hematology Oncology, Italian researchers summarized their results of treating 77 patients with pelvic Ewing sarcoma between 1979 and 1996 with a follow-up of over 10 years. None of these patients had distant metastasis at diagnosis.
Surgery Required to Cure Osteosarcoma (11/19/2002)
Osteosarcoma is a relatively rare cancer which occurs in adolescents and young adults. Osteosarcoma usually involves an extremity. Current treatment of osteosarcoma involves initial chemotherapy followed by surgery and then by further consolidative chemotherapy. Surgery usually consists of amputation or extensive local excision. This strategy has led to cure rates of 50-65% compared to cure rates of approximately 20% when surgery alone is used. The success of chemotherapy in improving the cure rate prompted researchers at MD Anderson Cancer Center to evaluate the feasibility of cure by chemotherapy alone. In a study that began in 1978 involving 31 patients, these researchers evaluated chemotherapy alone as treatment for osteosarcoma. They reported their findings in the November 15, 2002 issue of
Cancer.
Ethyol® May Prevent Granulocytopenia in Children Being Treated for Osteosarcoma (5/22/2002)
According to results recently published in the
Journal of Pediatric Hematology-Oncology, Ethyol® (amifostine) decreases the incidence of granulocytopenia in patients undergoing treatment for osteogenic sarcoma.
|
|
Patient Home
